D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

Investigators reviewed the real-world performance of patients with neovascular AMD switches from other anti-VEGF therapies to ...

Investigators evaluated the association between extended faricimab dosing and early macular leakage area resolution in ...

Q2 2025 Earnings Call Transcript August 5, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized -- LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.